Cannabis, Linked Emotions, and Adolescent Risk Study

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT06576076
Status
Recruiting
Apply to this trial

Conditions

  • Adolescent Behavior
  • Cannabis Use
  • Depression
  • Suicidal Ideation

Eligibility Criteria

Sex
ALL
Age
12 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Contingency management for cannabis abstinence — BEHAVIORAL
    Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.

Study Details

The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.

Key Dates

Start date
Feb 18, 2025
Status verified
Feb 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Cannabis Abstinence (CB-Abst)
    Those randomized to the abstinence condition will be asked to stop using cannabis for eight weeks. They will participate in a contingency management protocol, which uses an escalating remuneration schedule to incentivize abstinence. Abstinence is confirmed biochemically via progressively decreasing values of creatinine-adjusted THCCOOH.
  • No Intervention: Cannabis Monitoring (CB-Mon)
    Those randomized to the monitoring condition will be asked to make no changes to their cannabis use frequency or dose for the duration of the eight week study.
  • No Intervention: Pre-intervention Pooled Groups (EMA Phase 1 Only)
    All enrolled participants will participate in approximately two weeks of EMA data collection prior to being randomized and starting intervention procedures to characterize mood during baseline use as usual (CB-Abst or CB-Mon).

Primary Outcome Measure

Aim 1: Cannabis use in the last hour [ Time Frame: Weeks 1 - 2 (EMA Phase 1; Baseline Use as Usual) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HopsitalBostonMassachusetts02114
Randi M Schuster, PhD
[email protected]
617-643-6673
Julia Jashinski, MSW
[email protected]
617-643-1984

Find similar trials in Boston, MA

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Massachusetts General Hopsital· Boston, MA

Related Studies